Location History:
- Boston, MA (US) (2010)
- Brookline, MA (US) (2011)
- Boston-Jamaica Plain, MA (US) (2012)
Company Filing History:
Years Active: 2010-2012
Title: Inventor Spotlight: Steffen Helmling
Introduction
Steffen Helmling is a notable inventor based in Boston-Jamaica Plain, MA, USA. With a strong focus on biomedicine, he has contributed significantly to the field through his innovative work. Helmling holds a total of three patents which highlight his dedication to advancing scientific knowledge and technology.
Latest Patents
Among his recent innovations, one of the most remarkable patents is related to "Ghrelin binding nucleic acids." This invention involves nucleic acids that bind specifically to ghrelin, potentially offering new avenues for therapeutic interventions. Another significant patent pertains to "CGRP binding nucleic acids," which describes an antagonist for CGRP and amylin. This nucleic acid-based antagonist demonstrates the potential to target these crucial peptides, showcasing the versatility and impact of Helmling's research contributions.
Career Highlights
Steffen Helmling is currently associated with Noxxon Pharma AG, a company known for its focus on innovative biopharmaceuticals. His role at Noxxon Pharma exemplifies his commitment to advancing medical science, particularly in the development of new treatment modalities. Helmling's expertise in nucleic acid technologies positions him at the forefront of drug development within the competitive pharmaceutical sector.
Collaborations
Throughout his career, Helmling has collaborated with esteemed colleagues, including Christian Maasch and Sven Klussmann. These partnerships have likely strengthened his research efforts and contributed to the successful development of his patented technologies.
Conclusion
In summary, Steffen Helmling is an influential inventor whose work in the field of nucleic acid research is paving the way for novel therapeutic solutions. With a solid patent portfolio and a position at Noxxon Pharma AG, he continues to be a significant figure in the landscape of biomedicine. His innovative contributions hold promise for future advancements in healthcare and treatment options.